Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2022
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
10 August 2022 - Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the ...
Posted by Michael Wonder on 08 Aug 2022
SMC - August 2022 decisions
8 August 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 11 Jul 2022
SMC - July 2022 decisions
11 July 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 13 Jun 2022
SMC - June 2022 decisions
13 June 2022 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 10 May 2022
First treatment option indicated for CKD in Scotland for 20 years
10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy ...
Posted by Michael Wonder on 09 May 2022
SMC - May 2022 decisions
9 May 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 11 Apr 2022
SMC - April 2022 decisions
12 April 2022 - Advice on three new medicines for use in conditions including a rare and fatal genetic condition affecting ...
Posted by Michael Wonder on 15 Mar 2022
New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
8 March 2022 - A new UK wide health technology assessment access forum has been developed by partners including the ...
Posted by Michael Wonder on 10 Mar 2022
SMC accepts Lumykras (sotorasib) for locally advanced or metastatic non-small cell lung cancer for use on an interim basis by NHS Scotland
7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced ...
Posted by Michael Wonder on 09 Mar 2022
SMC approval welcome news for breast cancer patients
9 March 2022 - Trodelvy is accepted for use in metastatic triple negative breast cancer. patients who have already received two ...
Posted by Michael Wonder on 08 Mar 2022
Scottish Medicines Consortium update
7 March 2022 - Diurnal provides an update on the status of reimbursement of Efmody (modified release hydrocortisone) for NHS ...
Posted by Michael Wonder on 07 Mar 2022
SMC - March 2022 decisions
7 March 2022 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 10 Feb 2022
SMC approves Biogen’s Vumerity for patients with multiple sclerosis
9 February 2022 - The new, at home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple ...
Posted by Michael Wonder on 09 Feb 2022
Angelini Pharma’s Ontozry available for patients in Scotland with drug resistant epilepsy
9 February 2022 - SMC accepts promising new therapy which offers a better quality of life to patients with epilepsy ...
Posted by Michael Wonder on 08 Feb 2022
Cannabis-based medicine among batch of new drugs approved for use in Scotland
8 February 2022 - The medicines have been approved for use by the Scottish Medicines Consortium. ...